Lorus announces presentation of corporate overview at the Rodman and Renshaw Annual Healthcare Conference

                     -Presentation available by web cast-

    TORONTO, Nov. 6 /CNW/ - Lorus Therapeutics Inc. ('Lorus'), a
biopharmaceutical company specializing in the research, development and
commercialization of pharmaceutical products and technologies for the
management of cancer, announced today that on Wednesday, November 7, 2007, at
10:30 a.m. EST (Eastern Standard Time), Dr. Aiping H. Young, President and CEO
will present a corporate overview of the Company at the Acumen BioFin Rodman
and Renshaw 9th Annual Healthcare Conference. The presentation will be web
cast at http://www.wsw.com/webcast/rrshq12/lrp and will be available through
the Lorus website from November 7, 2007.
    The conference, which runs from November 5 to November 7, 2007, provides
informational service and networking opportunities for healthcare companies
and investors.

    About Lorus

    Lorus is a biopharmaceutical company focused on the research and
development of cancer therapies. Lorus' goal is to capitalize on its research,
preclinical, clinical and regulatory expertise by developing new drug
candidates that can be used, either alone, or in combination, to successfully
manage cancer. Through its own discovery efforts and an acquisition and
in-licensing program, Lorus is building a portfolio of promising anticancer
drugs. Late-stage clinical development and marketing may be done in
cooperation with strategic pharmaceutical partners. Lorus currently has
products in human clinical trials with a pipeline of seven clinical trials in
Phase II clinical trial programs, as well as one Phase II and one Phase III
clinical trial recently completed. Lorus Therapeutics Inc. is a public company
listed on the Toronto Stock Exchange under the symbol LOR, and on the American
Stock Exchange under the symbol LRP. Virulizin(R) is a registered trademark of
Lorus Therapeutics Inc.

    Forward Looking Statements

    Except for historical information, this press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, which reflect the Company's current expectation
and assumptions, and are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties, including, but not
limited to, changing market conditions, the Company's ability to obtain patent
protection and protect its intellectual property rights, commercialization
limitations imposed by intellectual property rights owned or controlled by
third parties, intellectual property liability rights and liability claims
asserted against the Company, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process, product development delays, the Company's ability
to attract and retain business partners and key personnel, future levels of
government funding, the Company's ability to obtain the capital required for
research, operations and marketing and other risks detailed from time-to-time
in the Company's ongoing quarterly filings, annual information forms, annual
reports and 40-F filings. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
    Lorus Therapeutics Inc.'s press releases are available through the
Company's Internet site: http://www.lorusthera.com.

For further information:

For further information: Enquiries: Lorus Therapeutics Inc., Dr. Saeid
Babaei, (416) 798-1200 ext. 490, ir@lorusthera.com

Organization Profile

Aptose Biosciences Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890